BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31416331)

  • 1. A Previously Unknown Drug-Drug Interaction Is Suspected in Delayed Elimination of Plasma Methotrexate in High-Dose Methotrexate Therapy.
    Ishizaki J; Nakano C; Kitagawa K; Suga Y; Sai Y
    Ann Pharmacother; 2020 Jan; 54(1):29-35. PubMed ID: 31416331
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcium Channel Blockers Possibly Delay the Elimination of Plasma Methotrexate in Patients Receiving High-Dose Methotrexate Therapy.
    Inose R; Takahashi K; Nanno S; Hino M; Nagayama K
    J Chemother; 2019 Feb; 31(1):30-34. PubMed ID: 30773130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
    Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
    Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia.
    Reiss SN; Buie LW; Adel N; Goldman DA; Devlin SM; Douer D
    Ann Hematol; 2016 Dec; 95(12):2009-2015. PubMed ID: 27542957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination.
    Bain E; Birhiray RE; Reeves DJ
    Ann Pharmacother; 2014 Feb; 48(2):292-6. PubMed ID: 24259648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Delayed Elimination of Methotrexate in Children, Adolescents and Young Adults With Osteosarcoma.
    Misaka KO; Suga Y; Staub Y; Tsubata A; Shimada T; Sai Y; Matsushita R
    In Vivo; 2020; 34(6):3459-3465. PubMed ID: 33144454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study.
    Schmidt D; Kristensen K; Schroeder H; Wehner PS; Rosthøj S; Heldrup J; Damsgaard L; Schmiegelow K; Mikkelsen TS
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27637. PubMed ID: 30835935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients.
    Zhang W; Zhang Q; Zheng TT; Zhen JC; Niu XH
    Chin Med J (Engl); 2016 Nov; 129(21):2530-2534. PubMed ID: 27779157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Serum Albumin Level Is a Risk Factor for Delayed Methotrexate Elimination in High-Dose Methotrexate Treatment.
    Kataoka T; Sakurashita H; Kajikawa K; Saeki Y; Taogoshi T; Matsuo H
    Ann Pharmacother; 2021 Oct; 55(10):1195-1202. PubMed ID: 33543634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
    Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
    Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate clearance and clinical toxicity in osteosarcoma following high-dose methotrexate therapy.
    Iqbal MP; Khursheed M; Mahboobali N
    J Pak Med Assoc; 1989 Feb; 39(2):38-42. PubMed ID: 2499702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy.
    Dupuis C; Mercier C; Yang C; Monjanel-Mouterde S; Ciccolini J; Fanciullino R; Pourroy B; Deville JL; Duffaud F; Bagarry-Liegey D; Durand A; Iliadis A; Favre R
    Anticancer Drugs; 2008 Mar; 19(3):267-73. PubMed ID: 18510172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of intravenous stronger neo-minophagen C and S-adenosyl-L-methionine in treatment of pregnant woman with chronic hepatitis B: a pilot study.
    Sun QF; Ding JG; Wang XF; Fu RQ; Yang JX; Hong L; Xu XJ; Wang JR; Wu JG; Xu DZ
    Med Sci Monit; 2010 Aug; 16(8):PR9-14. PubMed ID: 20671623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
    Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
    Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma.
    Young EP; Cheng WS; Bernhardt MB; Wang LL; Rainusso N; Foster JH
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28123. PubMed ID: 31867853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
    Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
    Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis C virus protein and iron in mice.
    Korenaga M; Hidaka I; Nishina S; Sakai A; Shinozaki A; Gondo T; Furutani T; Kawano H; Sakaida I; Hino K
    Liver Int; 2011 Apr; 31(4):552-60. PubMed ID: 21382166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate Elimination When Coadministered With Levetiracetam.
    Reeves D; DiDominick S; Finn S; Kim HJ; Shake A
    Ann Pharmacother; 2016 Dec; 50(12):1016-1022. PubMed ID: 27511814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.